The University of Massachusetts Amherst was awarded a $557,247 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from February 1, 2023 to January 31, 2026 to develop intracellular bacterial delivery of vaccine antigens to establish T-cell antitumor immunity in triple-negative breast cancer. The Military Medical Research and Development program supports innovative medical research with the goals of improving health care for service members and the public. This award will further those goals by investigating a novel vaccine delivery method that could help treat triple-negative breast cancer, a form of the disease lacking effective therapeutic options.
Generated 1/7/24, 2:00 AM